Previous close | 8.57 |
Open | 8.68 |
Bid | 5.00 x 800 |
Ask | 13.37 x 800 |
Day's range | 8.06 - 8.78 |
52-week range | 8.06 - 35.75 |
Volume | |
Avg. volume | 171,204 |
Market cap | 354.006M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.08 |
Earnings date | 10 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 36.22 |
CAMBRIDGE, Mass. & MONTREAL, May 09, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. & MONTREAL, May 05, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.